Skip to content
HISTORY

30 Years of Innovation

​​​​​​Over the past years, we have been transforming groundbreaking innovations into reality, from the development of advanced cell lines and processes to the manufacture of cutting-edge therapeutics.

History

ProBioGen was founded in 1994 as a spin-off from the Charité (one of the largest university hospitals in Europe) in Berlin, Germany. Renowned as the preferred partner for biopharmaceutical enterprises seeking unparalleled expertise in cell line development and manufacturing, ProBioGen stands as the epitome of excellence. Our esteemed partners place unwavering trust in our ability to deliver exceptional service quality, underpinned by a commitment to excellence that permeates every facet of our operations. Moreover, our partners benefit from our adaptable project and deal structures, designed to accommodate their unique needs and objectives. With a resolute dedication to responsiveness and flexibility, we swiftly address challenges and capitalize on opportunities, ensuring seamless collaboration and optimal outcomes for all stakeholders involved.

Years of Exprience

Production Sites

~

Patent Families

>

Stable Cell Lines

ProBioGen_Location_GTH_1994-2000_sw

 

1994 - 2000

1994 - ProBiogen´s foundation as a diagnostic company

2000 - Strategic shift to contract development and GMP manufacturing of therapeutic proteins

2000 - 2010

2001 – Establishment of cell line development platform (continuously optimized) 

2002 – Manufacturing authorization granted,  
using single-use perfusion bioreactors from the start 

2003 – Development of first designer cell line 

2005 – Issuance of more than 15 patent families 

2008 – First commercial license for AGE1.CR® duck cell line 

2010 – Strategic investor: Minapharm Pharmaceuticals

ProBioGen_Labor_2000 - 2010

 

ProBioGen_HQ_HBS_2010 - 2020

 

2010 - 2020

2011 - First commercial license for GlymaxX® ADCC enhancement technology

2013 - Launch of first product produced with CHO cell line

2016 - Launch of first product using AGE1.CR® duck cell line

2017 - Development of more than 400 stable cell lines

2019 - Two facilities in Berlin - Weißensee

2019 - Launch of DirectedLuck® Transposase

2020 - Capacity increase with 1000L single-use bioreactor

2020 - Today

2021 - Incorporation of the subsidiary MiGenTra GmbH

2022 – Three locations in Berlin-Weißensee

2023 – Launch of packaging and producer cell line Lenti.RiGHT®

2024 – Japanese patent for ProBioGen's DirectedLuck®

2024 – First GlymaxX® modified product approved by FDA 

2025 – Capacity increase with second 1000L single-use bioreactor

2025 – Diversification into viral manufacturing

ProBioGen_Kryolager_2010 - Today

 

Newsletter
Join for ProBioGen News - make sure to be always up-to-date and fully informed with our latest company announcements.